Stocks and Investing
Stocks and Investing
Mon, March 28, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Sun, March 27, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, March 25, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
John Abbott Maintained (ARCT) at Buy with Decreased Target to $105 on, Mar 25th, 2022
John Abbott of Wells Fargo, Maintained "Arcturus Therapeutics Holdings Inc." (ARCT) at Buy with Decreased Target from $107 to $105 on, Mar 25th, 2022.
John has made no other calls on ARCT in the last 4 months.
There are 2 other peers that have a rating on ARCT. Out of the 2 peers that are also analyzing ARCT, 1 agrees with John's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Steven Seedhouse of "Raymond James" Upgraded from Sell to Hold on, Monday, January 31st, 2022
This is the rating of the analyst that currently disagrees with John
- Yigal Nochomovitz of "Citigroup" Maintained at Strong Buy with Decreased Target to $86 on, Tuesday, March 15th, 2022
Contributing Sources